biostudies-literatureUnknown4(3)Shohdy KSThe persistence and reactivity of CAR T cells were enhanced by adding co-stimulatory domains, which is the basis of currently approved CAR-T cell therapies. However, this comes at the expense of increasing toxicities from the strong cytokine release effect. This is the first report from anti-CD19 CAR-T cell therapy with a single activation domain to show a favourable safety profile and clinical efficacy with two patients who achieved durable responses up to 28 months in a cohort with heavily pretreated B cell malignancies.EJHaem882-885https://www.ebi.ac.uk/biostudies/studies/S-EPMC10435680biostudies-literatureEvidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies.PMC10435680Chow SRothwell DKirillova NPillai MGilham DShohdy KSHawkins RGuest RThistlethwaite FfalseEvidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies.The persistence and reactivity of CAR T cells were enhanced by adding co-stimulatory domains, which is the basis of currently approved CAR-T cell therapies. However, this comes at the expense of increasing toxicities from the strong cytokine release effect. This is the first report from anti-CD19 CAR-T cell therapy with a single activation domain to show a favourable safety profile and clinical efficacy with two patients who achieved durable responses up to 28 months in a cohort with heavily pretreated B cell malignancies.2023-01-01T00:00:00Z2023 Aug2026-06-04T08:02:55.147Z2025-04-05T15:56:08.396ZS-EPMC104356803760188910.1002/jha2.731